Skip to main content

Table 2 Correlation of PDGFR A13 and B19 mutational status and clinical-pathological features

From: PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome

Clinical features PDGFRα exon 13 PDGFRβ exon 19
  WT N (%) SNP N (%) p WT N (%) SNP N (%) p
Gender    0.754    0.346
 · Female 24 (85.7) 4 (14.3)   10 (34.5) 19 (65.5)  
 · Male 36 (80.0) 9 (20.0)   23 (46.9) 26 (53.1)  
Age    0.127    0.653
 · ≤ 68-years old (median) 34 (89.5) 4 (10.5)   18 (45.0) 22 (55.0)  
 · > 68-years old (median) 26 (74.3) 9 (25.7)   15 (39.5) 23 (60.5)  
CEA (carcinoembryonic antigen)    1.000    0.813
 · Within normal range 39 (83.0) 8 (17.0)   21 (41.2) 30 (58.8)  
 · ≥ ULN (5 ng/ml) 21 (80.8) 5 (19.2)   12 (44.4) 15 (55.6)  
Primary tumour location    1.000    0.051
 · Colon 47 (82.5) 10 (17.5)   22 (36.1) 39 (63.9)  
Rectum 13 (81.3) 3 (18.8)   11 (64.7) 6 (35.3)  
Tumour histology    0.401    0.221
 · Conventional adenocarcinoma 52 (83.9) 10 (16.1)   30 (45.5) 36 (54.5)  
 · Mucinous or colloid adenocarcinoma 8 (72.7) 3 (27.3)   3 (25.0) 9 (75.0)  
TNM stage    0.196    0.170
 · I-II 23 (92.0) 2 (8.0)   8 (30.8) 18 (69.2)  
 · III-IV 37 (78.7) 10 (21.3)   24 (47.1) 27 (52.9)  
Tumour differentiation    0.053    0.586
 · Well differentiated 15 (100) 0 (0.0)   7 (36.8) 12 (63.3)  
 · Moderately or poorly differentiated 37 (77.1) 11 (22.9)   23 (47.9) 25 (52.1)  
Surgery of primary tumor    0.578    0.389
 · Yes 55 (80.9) 13 (19.1)   32 (43.8) 41 (56.2)  
 · No 5 (100.0) 0 (0.0)   1 (20.0) 4 (80.0)  
Surgery of metastasis    0.953    0.451
 · Yes 13 (86.7) 2 (13.3)   9 (50.0) 9 (50.0)  
 · No 47 (81.0) 11 (19.0)   24 (40.0) 24 (40.0)  
Adjuvant chemotherapy    0.295    0.986
 · Yes 28 (87.5) 4 (12.5)   14 (42.4) 19 (57.6)  
 · No 32 (78.0) 9 (22.0)   19 (42.2) 26 (57.8)  
Chemotherapy for advanced disease    0.683    0.929
 · Yes 36 (83.7) 7 (16.3)   18 (41.9) 25 (58.1)  
 · No 24 (80.0) 6 (20.0)   15 (42.9) 20 (57.1)